focus -WSS

focus

author：focus 2025-10-01 12:35:30 - browse：968

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： The Affordable Care Act has saved billions in health care costs

WSS

How generative AI ratchets up security threats for health systems

In medicine, common shorthands can shortchange care

Pancreatic cancer early detection could be helped by AI

Biogen walks away from Aduhelm, years after polarizing approval

Bernie Sanders is gearing up to subpoena pharma CEOs

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Wikipedia

focus

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

Pancreatic cancer early detection could be helped by AI

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Peter Hotez and the public health issue of online harassment

Trump Jan. 6 attorney John Lauro is ex

Anesthesiologist group: stop taking Ozempic before surgery

Philips to halt sales of sleep apnea machines in U.S.

Jerome Adams on the need for new antivirals for Covid

Why Medicare shouldn’t cover every FDA

hotspot

'The Exorcist' director William Friedkin dead at 87

Health Care Service Corp to buy Cigna Medicare Advantage plans

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

How generative AI ratchets up security threats for health systems

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Bernie Sanders is gearing up to subpoena pharma CEOs

hotspot

Wikipedia

Wikipedia

hotspot